Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate

氢溴酸特力利汀/卡格列净

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTeneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate
Drug Alias Name氢溴酸特力利汀/卡格列净水合物Canagliflozin/Teneligliptin HydrobromideTeneligliptin Hydrobromid/Canagliflozin氢溴酸特力利汀•卡格列净Teneligliptin Hydrobromide Hydrate and Canagliflozin Hemihydrate +[9] 
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2017/07/03
Country/TerritoryJapan
CombinationsYes Teneligliptin Hydrobromide HydrateCanagliflozin Hemihydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma CorpDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co LtdMitsubishi Tanabe Pharma
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BH
Related LinksN/A